keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant chemotherapy bladder cancer

keyword
https://www.readbyqxmd.com/read/28105470/bladder-cancer-segmentation-in-ct-for-treatment-response-assessment-application-of-deep-learning-convolution-neural-network-a-pilot-study
#1
COMMENT
Kenny H Cha, Lubomir M Hadjiiski, Ravi K Samala, Heang-Ping Chan, Richard H Cohan, Elaine M Caoili, Chintana Paramagul, Ajjai Alva, Alon Z Weizer
Assessing the response of bladder cancer to neoadjuvant chemotherapy is crucial for reducing morbidity and increasing quality of life of patients. Changes in tumor volume during treatment is generally used to predict treatment outcome. We are developing a method for bladder cancer segmentation in CT using a pilot data set of 62 cases. 65 000 regions of interests were extracted from pre-treatment CT images to train a deep-learning convolution neural network (DL-CNN) for tumor boundary detection using leave-one-case-out cross-validation...
December 2016: Tomography: a Journal for Imaging Research
https://www.readbyqxmd.com/read/28104421/assessing-cancer-progression-and-stable-disease-after-neoadjuvant-chemotherapy-for-organ-confined-muscle-invasive-bladder-cancer
#2
Meera R Chappidi, Max Kates, Aaron Brant, Alexander S Baras, George J Netto, Phillip M Pierorazio, Noah M Hahn, Trinity J Bivalacqua
OBJECTIVE: To propose and validate a new approach to stratify clinically staged organ-confined muscle-invasive bladder cancer patients (cT2N0M0) that are pathologic non-responders to neoadjuvant chemotherapy (NAC) to better characterize NAC non-response. METHODS: We retrospectively identified radical cystectomy patients with cT2N0M0 disease at our institution (2005-2014) and in the National Cancer Database (NCDB, 2004-2012) for external validation. Patients were stratified as stable (pT2N0M0) or progressors (>pT2 and/or pN+)...
January 16, 2017: Urology
https://www.readbyqxmd.com/read/28078533/risk-factors-for-intravesical-recurrence-after-nephroureterectomy-in-patients-with-upper-urinary-tract-urothelial-carcinoma
#3
Ryo Yamashita, Reiko Watanabe, Ichiro Ito, Hideo Shinsaka, Masafumi Nakamura, Masato Matsuzaki, Masashi Niwakawa
PURPOSE: To determine major risk factors for bladder cancer (BC) recurrence after nephroureterectomy (Nux) by focusing on the pathologic appearances of tumors in upper urinary tract urothelial carcinomas (UUTUCs). METHODS: We performed 147 Nux procedures between November 2002 and September 2015. Forty-eight patients were excluded because of a history of BC (28 patients), previous or concurrent radical cystectomy (9 patients), neoadjuvant chemotherapy (5 patients), and other reasons (6 patients)...
January 11, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28049550/gec-estro-acrop-recommendations-for-performing-bladder-sparing-treatment-with-brachytherapy-for-muscle-invasive-bladder-carcinoma
#4
Bradley R Pieters, Elzbieta van der Steen-Banasik, Geert A Smits, Marisol De Brabandere, Alberto Bossi, Erik Van Limbergen
The standard treatment for muscle-invasive bladder cancer (MIBC) is a radical cystectomy with pelvic lymph node dissection with or without neoadjuvant chemotherapy. In selected cases a bladder sparing approach is possible, for example a limited surgical excision combined with external beam radiotherapy and brachytherapy. To perform brachytherapy flexible catheters have to be implanted in the bladder wall. The implantation is done either by the open retropubic approach or the endoscopic surgical approach. The largest experience for brachytherapy is with low-dose rate and pulsed-dose rate, although some short-term experience with high-dose rate is also reported...
December 31, 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28041996/utilization-of-perioperative-systemic-chemotherapy-in-upper-tract-urothelial-carcinoma
#5
Greg E Gin, Nora H Ruel, Steven V Kardos, John P Sfakianos, Edward Uchio, Clayton S Lau, Bertram E Yuh
INTRODUCTION: Evidence for the use of perioperative chemotherapy (PC) in upper tract urothelial carcinoma (UTUC) is largely derived from level I evidence for invasive urothelial carcinoma of the bladder (UCB). There has been an increase in PC for urothelial carcinoma of the bladder, as it has disseminated into clinical practice. Therefore, we sought to not only analyze trends in the utilization of PC in UTUC, but also assess factors associated with its use in a large cancer registry database...
December 29, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/28035325/effect-of-neoadjuvant-chemotherapy-on-renal-function-following-radical-cystectomy-is-there-a%C3%A2-meaningful-impact
#6
Thenappan Chandrasekar, Neil Pugashetti, Blythe Durbin-Johnson, Marc A Dall'Era, Christopher P Evans, Ralph W deVere White, Stanley A Yap
Objective: To evaluate the patterns of impact of neoadjuvant chemotherapy (NAC) on renal function across the initial year following treatment for muscle-invasive bladder cancer (MIBC) with radical cystectomy (RC). Methods: We reviewed the charts of 241 patients who underwent RC for urothelial carcinoma of the bladder between 2003-14 at our institution. Renal function was evaluated at multiple time points (pre-chemotherapy, pre-operatively, post-operatively, 6-12 months follow-up), and then classified by CKD staging...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035322/micropapillary-bladder-cancer-insights-from-the-national-cancer-database
#7
Wilson Sui, Justin T Matulay, Maxwell B James, Ifeanyi C Onyeji, Marissa C Theofanides, Arindam RoyChoudhury, G Joel DeCastro, Sven Wenske
Introduction: Micropapillary bladder cancer (MPBC) is a variant histology of urothelial carcinoma (UC) that is associated with poor outcomes however given its rarity, little is known outside of institutional reports. We sought to use a population-level cancer database to assess survival outcomes in patients treated with surgery, radiation therapy and/or chemotherapy. Materials and Methods: The National Cancer Database (NCDB) was queried for all cases of MPBC and UC using International Classification of Disease-O-3 morphologic codes between 2004-2014...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28025135/doxorubicin-enhances-the-capacity-of-b-cells-to-activate-t-cells-in-urothelial-urinary-bladder-cancer
#8
A Ali Zirakzadeh, Johan Kinn, David Krantz, Robert Rosenblatt, Malin E Winerdal, Jin Hu, Ciputra Adijaya Hartana, Christian Lundgren, Emma Ahlén Bergman, Markus Johansson, Benny Holmström, Johan Hansson, Alexander Sidikii, Janos Vasko, Per Marits, Amir Sherif, Ola Winqvist
Cancer is currently treated by a combination of therapies, including chemotherapy which is believed to suppress the immune system. Combination of immunotherapy and chemotherapy correlates with improved survival but needs careful planning in order to achieve a synergistic effect. In this study we have demonstrated that Doxorubicin treatment of B cells resulted in increased expression of CD86 and concordantly increased CD4(+) T cell activation in presence of superantigen, an effect that was inhibited by addition of a CD86 blocking antibody...
December 23, 2016: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/27991416/small-cell-carcinoma-of-the-bladder-20-year-single-institution-retrospective-review
#9
Kyungsuk Jung, Pooja Ghatalia, Samuel Litwin, Eric M Horwitz, Robert G Uzzo, Richard E Greenberg, Rosalia Viterbo, Daniel M Geynisman, Alexander Kutikov, Elizabeth R Plimack, Marc C Smaldone, Yu-Ning Wong, Marijo Bilusic
INTRODUCTION: Small-cell carcinoma of the bladder is a poorly differentiated neoplasm with aggressive behavior. We analyzed clinical outcomes of patients who were treated at our institution to identify an optimal treatment strategy. MATERIALS AND METHODS: Retrospective chart analysis was performed for patients who were treated for small-cell carcinoma of the bladder at Fox Chase Cancer Center between 1995 and 2015. Survival was compared between different treatment periods (before January 2010 vs...
September 30, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27980085/the-feasibility-and-effectiveness-of-robot-assisted-radical-cystectomy-after-neoadjuvant-chemotherapy-in-patients-with-muscle-invasive-bladder-cancer
#10
Takuya Koie, Chikara Ohyama, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Tohru Yoneyama, Yuki Tobisawa, Atsushi Yamauchi, Toru Shimazui, Mikinobu Ohtani
OBJECTIVES: The aim of this study was to compare 29 muscle-invasive bladder cancer patients who received neoadjuvant chemotherapy (NAC) followed by immediate robot-assisted radical cystectomy (RARC) with those who underwent minimum-incision endoscopic RC (MIE-RC). METHODS: We retrospectively reviewed the charts of 430 consecutive patients who underwent RC and bilateral pelvic node dissection (PLND) between May 1994 and July 2016. Our study focused on patients with MIBC who had histologically confirmed stage T2-T4aN0M0 urothelial carcinoma of the bladder and received NAC prior to surgery...
December 15, 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27960233/iatrogenic-changes-in-the-urinary-tract
#11
REVIEW
Antonio Lopez-Beltran, Gladell P Paner, Rodolfo Montironi, Maria R Raspollini, Liang Cheng
A handful of therapeutic procedures are used to treat malignancies of the urinary tract, most frequently intravesical immunotherapy or chemotherapy, but also neoadjuvant systemic chemotherapy. These treatment modalities produce morphological changes in the urothelium that can be mistaken for carcinoma; in particular, these therapies frequently mimic urothelial carcinoma in situ (CIS) urothelial dysplasia or true invasive neoplasia. Drugs such as mitomycin C used after transurethral resection of bladder tumour to reduce recurrences, bacillus Calmette-Guérin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy disease-specific survival are examples of therapy-related atypia seen in the urinary tract...
January 2017: Histopathology
https://www.readbyqxmd.com/read/27908636/impact-of-neoadjuvant-chemotherapy-on-complications-of-minimally-invasive-radical-cystectomy
#12
D Lizée, R S Salas, E Barret, M Galiano, E Di Trapani, F Montorsi, X Cathelineau
BACKGROUND: Neoadjuvant chemotherapy (NC) before minimally invasive radical cystectomy (MIRC) is considered a standard of care in muscle-invasive bladder cancer or recurrent high-risk non-muscle-invasive bladder cancer. OBJECTIVE: To evaluate the impact of NC on morbidity and mortality after MIRC. DESIGN, SETTING, AND PARTICIPANTS: We prospectively evaluated 135 patients who underwent MIRC (laparoscopic: n=100; robotic: n=35) between 2007 and 2013 with ≥90 days of follow-up (median age: 66 year)...
November 28, 2016: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/27900539/seom-clinical-guideline-for-treatment-of-muscle-invasive-and-metastatic-urothelial-bladder-cancer-2016
#13
M Lázaro, E Gallardo, M Doménech, Á Pinto, A González Del Alba, J Puente, O Fernández, A Font, N Lainez, S Vázquez
The goal of this article is to provide recommendations for the diagnosis and treatment of muscle-invasive and metastatic bladder cancer. The diagnosis of muscle-invasive bladder cancer is made by pathologic evaluation after transurethral resection. Recently, a molecular classification has been proposed. Staging of muscle-invasive bladder cancer must be done by computed tomography scans of the chest, abdomen and pelvis and classified on the basis of UICC system. Radical cystectomy and lymph node dissection are the treatment of choice...
December 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27896578/is-there-evidence-for-a-close-connection-between-side-of-intravesical-tumor-location-and-ipsilateral-lymphatic-spread-in-lymph-node-positive-bladder-cancer-patients-at-radical-cystectomy-results-of-the-prometrics-2011-database
#14
M May, C Protzel, M W Vetterlein, M Gierth, J Noldus, A Karl, T Grimm, B Wullich, M O Grimm, P Nuhn, P J Bastian, J Roigas, B Hadaschik, C Gilfrich, M Burger, M Fisch, S Brookman-May, A Aziz, O W Hakenberg
PURPOSE: To evaluate the possible association between bladder tumor location and the laterality of positive lymph nodes (LN) in a prospectively collected multi-institutional radical cystectomy (RC) series. METHODS: The study population included 148 node-positive bladder cancer (BC) patients undergoing RC and pelvic lymph node dissection in 2011 without neoadjuvant chemotherapy and without distant metastasis. Tumor location was classified as right, left or bilateral and compared to the laterality of positive pelvic LN...
November 28, 2016: International Urology and Nephrology
https://www.readbyqxmd.com/read/27878946/targeted-inhibition-of-polo-like-kinase-1-by-a-novel-small-molecule-inhibitor-induces-mitotic-catastrophe-and-apoptosis-in-human-bladder-cancer-cells
#15
Zhe Zhang, Guojun Zhang, Chuize Kong
Bladder cancer is a common cancer with particularly high recurrence after transurethral resection. Despite improvements in neoadjuvant chemotherapy, the outcome of patients with advanced bladder cancer has changed very little. In this study, the anti-tumour activities of a novel Polo-like kinase 1 (PLK1) inhibitor (RO3280) was evaluated in vitro and in vivo in the bladder carcinoma cell lines 5637 and T24. MTT assays, colony-formation assays, flow cytometry, cell morphological analysis and trypan blue exclusion assays were used to examine the proliferation, cell cycle distribution and apoptosis of bladder carcinoma cells with or without RO3280 treatment...
November 23, 2016: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/27874062/systemic-perioperative-management-of-muscle-invasive-bladder-cancer-and-future-horizons
#16
REVIEW
Samuel A Funt, Jonathan E Rosenberg
Many patients diagnosed with muscle-invasive bladder cancer (MIBC) will develop distant metastatic disease. Over the past three decades, perioperative cisplatin-based chemotherapy has been investigated for its ability to reduce the number of deaths from bladder cancer. Insufficient evidence is available to fully support the use of such chemotherapy in the adjuvant setting; however, neoadjuvant cisplatin-based combination chemotherapy has become a standard of care for eligible patients based on the improved disease-specific and overall survival demonstrated in two randomized phase III trials, compared with surgery alone...
November 22, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27846935/-ccafu-french-national-guidelines-2016-2018-on-bladder-cancer
#17
M Rouprêt, Y Neuzillet, A Masson-Lecomte, P Colin, E Compérat, F Dubosq, N Houédé, S Larré, G Pignot, P Puech, M Roumiguié, E Xylinas, A Méjean
OBJECTIVE: The purpose of the guidelines national committee CCAFU on bladder cancer was to propose updated french guidelines for non-muscle invasive (NMIBC) and invasive (MIBC) bladder cancers. METHODS: A Medline search was achieved between 2013 and 2016, as regards diagnosis, options of treatment and follow-up of bladder cancer, to evaluate different references with levels of evidence. RESULTS: Diagnosis of NMIBC (Ta, T1, CIS) is based on a complete deep resection of the tumour...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27822081/the-danish-bladder-cancer-database
#18
REVIEW
Erik Hansen, Heidi Larsson, Mette Nørgaard, Peter Thind, Jørgen Bjerggaard Jensen
AIM OF DATABASE: The aim of the Danish Bladder Cancer Database (DaBlaCa-data) is to monitor the treatment of all patients diagnosed with invasive bladder cancer (BC) in Denmark. STUDY POPULATION: All patients diagnosed with BC in Denmark from 2012 onward were included in the study. Results presented in this paper are predominantly from the 2013 population. MAIN VARIABLES: In 2013, 970 patients were diagnosed with BC in Denmark and were included in a preliminary report from the database...
2016: Clinical Epidemiology
https://www.readbyqxmd.com/read/27803966/contemporary-treatment-patterns-and-outcomes-of-sarcomatoid-bladder-cancer
#19
Wilson Sui, Justin T Matulay, Ifeanyi C Onyeji, Marissa C Theofanides, Maxwell B James, Arindam RoyChoudhury, Sven Wenske, G Joel DeCastro
PURPOSE: To characterize the treatment patterns and survival outcomes of sarcomatoid bladder cancer, a rare urothelial variant histology using a large population level cancer database. METHODS: The National Cancer Database was queried for all cases of sarcomatoid bladder cancer using International Classification of Disease-O-3 morphologic code 8122 between 2004 and 2014. Primary outcome was overall survival. RESULTS: A total of 489 patients met our inclusion criteria and were included in our analysis...
November 1, 2016: World Journal of Urology
https://www.readbyqxmd.com/read/27787873/neutrophil-to-lymphocyte-ratio-as-a-bladder-cancer-biomarker-assessing-prognostic-and-predictive-value-in-swog-8710
#20
Eric Ojerholm, Andrew Smith, Wei-Ting Hwang, Brian C Baumann, Kai N Tucker, Seth P Lerner, Ronac Mamtani, Ben Boursi, John P Christodouleas
BACKGROUND: Risk stratification is a major challenge in bladder cancer (BC), and a biomarker is needed. Multiple studies have reported the neutrophil-to-lymphocyte ratio (NLR) as a promising candidate; however, these analyses have methodological limitations. Therefore, the authors performed a category B biomarker study to test whether NLR is prognostic for overall survival (OS) after curative treatment or is predictive for the survival benefit from neoadjuvant chemotherapy (NAC). METHODS: This study is an unplanned secondary analysis of SWOG 8710, a randomized phase 3 trial that assessed cystectomy with or without NAC in 317 patients with muscle-invasive BC...
October 27, 2016: Cancer
keyword
keyword
40909
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"